PrimaryLogo_Mango-05.png
MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
August 15, 2024 09:25 ET | Mangoceuticals, Inc.
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent
August 13, 2024 16:00 ET | Mangoceuticals, Inc.
Dallas, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
August 09, 2024 08:15 ET | Mangoceuticals, Inc.
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology
July 24, 2024 08:15 ET | Mangoceuticals, Inc.
Dallas, Texas, July 24, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a leader in men’s health and wellness products including erectile dysfunction (ED),...
PrimaryLogo_Mango-05.png
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access
July 18, 2024 16:05 ET | Mangoceuticals, Inc.
DALLAS, TEXAS, July 18, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts
July 16, 2024 08:20 ET | Mangoceuticals, Inc.
DALLAS, TX, July 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and...
PrimaryLogo_Mango-05.png
MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department
July 12, 2024 13:30 ET | Mangoceuticals, Inc.
DALLAS, TEXAS, July 12, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets
July 11, 2024 08:15 ET | Mangoceuticals, Inc.
DALLAS, TEXAS, July 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
June 06, 2024 08:30 ET | Mangoceuticals, Inc.
Dallas, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
May 28, 2024 08:30 ET | Mangoceuticals, Inc.
Dallas, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...